Abstract
Background Overt hepatitis B virus (HBV) infection is defined as infection with detectable surface antigen (HBsAg) in patient’s blood. End stage renal disease (ESRD) patients who are on maintenance hemodialysis (HD) are considered to be strong candidates for HBV infection due to prolonged vascular access via HD procedure. In addition, the differences in host immune response can be one of the reasons for the various clinical presentations of HBV infection. Polymorphisms of genes encoding the pro-inflammatory and anti-inflammatory cytokines, which are responsible for regulation of the immune response, can affect the clinical presentation of the infection. Particularly, the polymorphisms of the genes encoding cytokines such as interleukin 6 (IL6) and interleukin 10 (IL10).
Aim This current study aimed to compare serum levels and allelic variant of IL-6 -174G/C and IL-10- 1082G/A polymorphisms in patients with overt hepatitis B and end stage renal disease hepatitis B patients in Khartoum State- Sudan.
Method Case control study has been conducted to detect the IL-6 -174G/C and IL-10- 1082G/A polymorphisms using SSP-PCR and serum level of IL6 and IL10 using ELISA in 68 from Hepatitis B patient (37 overt hepatitis B patients and 31 end stage renal disease hepatitis B patients
Result The result showed that there was no statistically difference in IL6 (174G/C) and IL10 (1082G/A) Allelic frequencies (P. value = .738, .194 respectively), Serum level (P. value = 0.36, .179 respectively) between two groups. In addition there is no significant correlation between the IL6 (174G/C) and IL10 (1082G/A) and serum level in study groups.
Conclusion The Allelic Variant of IL-6 -174G/C and IL-10- 1082G/A Polymorphisms and serum levels could not play apart in complication of hepatitis B in end stage renal disease patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethical Committee of Scientific Research Deanship Alneelain University, and informed consent obtained from each participant before sample collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
